Our commitment to fostering a culture of open communication and collaboration is exemplified through our annual global engagement survey results.
Our safety measures led to a decline in our number of accidents with absence, from 6 in 2022 to 3 in 2023.
Regular safety dialogues with workers councils or employees
Monthly safety inspections across all production facilities
Digitalization of near miss frequency reporting
Embracing a multi-dimensional perspective, we acknowledge diversity in terms of physical, psychological, social, lifestyle, and cognitive dimensions, actively engaging with a number of employee focus groups to seek input on improving inclusion across ALK.
Recognizing the pivotal role of development in enhancing employee retention and performance, we integrate development agreements as a fundamental component of our annual people processes for all employees to gain a clear direction for their learning and growth opportunities.
Our Leading with Impact programme provides training in agile- and inclusive leadership across the organization. In addition, our talent programmes foster a culture of continuous learning and growth.
Value chain workers
ALK's Third-party Code of Conduct outlines the standards of behavior that we expect from all third parties globally when it comes to business conduct and treatment of employees. The Third-party Code of Conduct is an integrated part of our GxP (good practice) supplier agreements.
To address supplier risk, we utilize an external supplier evaluation platform to identify environment, labor & human rights, and procurement risks. 400+ suppliers approved for our GxP processes have been screened, none of which have been identified as high-risk.
Consumers and end users
Social inclusion of consumers and end-users
With over 500 million people worldwide affected by respiratory allergies, many suffer without adequate support and treatment options. We wish to improve access to clinically proven allergy diagnosis and treatment solutions, ultimately improving the lives of allergy sufferers globally. As part of our efforts to ensure inclusivity and accessibility of our allergy medicines, we are prioritising two key areas: extending our geographical reach and obtaining approvals for children and adolescents.
Conducting clinical trials
In our ongoing efforts to develop innovative treatments for allergies, our clinical trials uphold safety, privacy, ethics and respect.
We adhere to:
• the European Federation of Pharmaceutical Industries and Associations (EFPIA)
• the Pharmaceutical Research and Manufactures of America (PhRMA) Principles for Responsible Clinical Trial Data Sharing.
Safety of people with allergies
ALK has a rigorous safety reporting system in place ensuring that safety data from any source, including clinical trials, are collected and analysed systematically by our global pharmacovigilance team. This ensures that the safety profile of our products is optimized for the benefit of users, and that the relevant authorities can be made aware of any safety issue arising from our products to facilitate immediate action.
Education of healthcare professionals
We engage systematically in educational activities, training and dialogue with healthcare professionals to elevate the standard of care in allergy diagnosis and treatment. Much of our engagement is done digitally enabling us to reach more healthcare professionals and reduce our climate impact.
Policy downloads
Code of conduct
Diversity and Inclusion Policy
UK Modern Slavery Act statement 2023
Partnering for sustainability
The challenges of social action require commitments and partnerships.
Last updated:
30.09.2024
Social